Sema4 Holdings Corp. provided earnings guidance for the second half and full year 2022. For the second half, the company expects revenue in the range of $154 million - $164 million.

For the full year, the company expects revenue to be $245 million - $255 million, reflecting the inclusion of GeneDx's results for the eight months of ownership in 2022. Embedded in this revenue guidance is a $24 million reduction in revenue due to estimated change of Sema4's revenue related to periods prior to 2022 and a more conservative outlook on volumes and pricing trends within reproductive health product lines for the remainder of the year.